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ABSTRACT 
Meningococcal oligosaccharide- and polysaccharide-protein 
conjugate vaccines are under investigation in humans for pre- 
vention of disease caused by serogroup A and C organisms. 
These vaccines appear to be safe and well tolerated. Repeated 
immunization of infants and toddlers with meningococcal C 
conjugate vaccines, given either alone or in a single formula- 
tion with meningococcal A conjugate vaccine, elicits boostable 
increases in serum meningococcal C bactericidal antibody titer. 
The C conjugate vaccine also induces memory B cells that are 
capable of responding to a subsequent immunization with 
unconjugated meningococcal polysaccharide vaccine. In con- 
trast, immunization with unconjugated meningococcal C poly- 
saccharide vaccine in these age groups is much less 
immunogenic and does not induce long-term immunologic 
memory. Less data are available on immune responses to 
meningococcal A conjugate vaccines, However, toddlers vac- 
cinated in the United States with a meningococcal A vaccine 
combined with a meningococcal C conjugate vaccine, show 
much higher meningococcal A bactericidal antibody responses 
and greater induction of memory B cells than control toddlers 
given unconjugated meningococcal polysaccharide vaccine. 
The same conjugate vaccine was given to infants in Gambia, 
where there were no significant differences in the magnitude of 
the anti-A antibody responses, or in induction of memory B 
cells, compared to control infants given unconjugated poly- 
saccharide vaccine. Meningococcal B conjugate vaccines also 
are under development. In experimental animals, these vac- 
cines are much less immunogenic than A or C conjugates, 
probably because of immunologic tolerance induced to the B 
polysaccharide by exposure to cross-reacting polysialic acid 
expressed in the brain and other tissues of the host. To cir- 
cumvent tolerance, conjugate vaccines have been prepared 
from derivatized meningococcal B polysaccharide, where N- 
propionyl groups have been substituted for N-acetyl groups. In 
experimental animals, such conjugates show increased 
immunogenicity, including development of bactericidal anti- 
bodies, but a subset of the antibodies still shows strong auto- 
antibody activity with host polysialic acid. Although there is no 
direct evidence that such antibodies are harmful, it will be a 
difficult task to prove that such a meningococcal B vaccine is 
safe to use in humans. 
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Meningococcal polysaccharide vaccines are available for 
prevention of invasive diseases caused by Neisseria 
meningitidis, serogroups A, C, Y, and W135. Protection 
correlates with the ability of vaccination to induce serum 
complement-mediated bactericidal antibody.’ In general, 
the antibody responses to these unconjugated polysac- 
charides are age-dependent: these vaccines are highly 
effective in adults, but with the exception of meningo- 
coccal A polysaccharide, they elicit negligible or incom- 
plete and short-lived protection in infants and preschool 
children.2-4 For reasons that are unknown, meningococ- 
cal A polysaccharide is immunogenic and protective in 
infants as young as 3 months of age.3,5 However, dura- 
tion of protection to meningococcal A is age-dependent 
in infants, declining dramatically within 1 to 2 years.3 
Polysaccharide vaccines for prevention of disease caused 
by serogroup B meningococcal strains are not available. 
The group B polysaccharide is a poor immunogen at all 
ages, possibly because of immunologic tolerance induced 
in the host by the presence of cross-reactive polysialy- 
ated glycoproteins in fetal and adult tissues.” 
Most polysaccharides appear to elicit antibody 
responses largely without the need for T-cell help (i.e., 
they are thymic-independent, or TI antigens). Conjugation 
of a polysaccharide to a protein carrier profoundly alters 
the immunologic properties of the polysaccharide, con- 
verting it from a TI to a thymic-dependent (TD) antigen. 
In the resulting TD conjugate, the immunogenicity of the 
polysaccharide is greatly enhanced, giving rise to IgG 
anticapsular antibodies and memory B cells. 
EXPERIENCE 
Haemop~ilus i@uenzae Type b Conjugate Vaccines 
Much has been learned about human immunity to poly- 
saccharide-protein conjugate vaccines from studies of 
Haemophilus injluenzae type b (Hib) vaccines. Com- 
pared to unconjugated Hib polysaccharide, the immuno- 
genicity of the conjugated Hib polysaccharide in infants 
is greatly enhanced, and repeated injections elicit IgG 
booster responses, whereas such responses are not 
observed after repeated doses of unconjugated Hib poly- 
saccharide.’ Serum antibody to the type b capsule con- 
fers protection against invasive Hib disease. In addition, 
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Hib conjugate vaccination primes for long-term immuno- 
logic memory to the Hib polysaccharide, a property not 
elicited by vaccination with unconjugated Hib polysac- 
charide, or even after recovery from Hib disease.8 The 
ability to develop memory B cells, which leads to rapid 
IgG anticapsular antibody responses upon encountering 
Hib organisms, may be an important alternative mecha- 
nism of protection against developing disease in vacci- 
nated individuals who have shown subprotective antibody 
responses to Hib conjugate vaccination.9 Induction of 
immunologic memory also may be important for con- 
ferring protection to children whose serum antibody con- 
centrations have declined to below the protective level.‘O 
Haemophilus influenzae type b conjugate vaccines 
are effective in two other important ways: first, the anti- 
capsular antibody elicited by repeated injections of Hib 
conjugate vaccines undergoes affinity maturation 
(Granoff DM. Unpublished). The resulting higher avidity 
antibodies are more efficient at activating complement- 
mediated bacteriolysis or opsonization of Hib than lower 
avidity antibodies. 11,12 Second, immunization with Hib 
conjugate vaccines not only protects the individual from 
developing invasive Hib disease by inducing protective 
immunity, but also lowers the rate of nasopharyngeal col- 
onization and transmission of Hib in the population.13J4 
By this mechanism, Hib conjugate vaccination can have 
a better effect on decreasing the incidence of Hib dis- 
ease in the population than would be predicted based on 
vaccine coverage. lj It seems likely that meningococcal 
polysaccharide-protein conjugate vaccines will share sim- 
ilar properties, but these areas require further study. 
Meningococcal Polysaccharide-Protein Conjugate 
Vaccines 
Meningococcal oligosaccharide- and polysaccharide- 
protein conjugate vaccines have been prepared for pre- 
vention of diseases caused by serogroup A, B, and C 
organisms. 16-*0 To date, data from humans are limited to 
serogroup A and C meningococcal oligosaccharide- 
protein conjugate vaccines. A first-generation prototype 
vaccine was prepared at Chiron Vaccines (Emeryville, 
CA) using meningococcal A and C oligosaccharides that 
were independently coupled to CRM,9, carrier protein 
(a cross-reactive nontoxic mutant diphtheria toxin).2o As 
summarized in Figure 1, the conjugation method is based 
on selective end-reducing group activation of oligosac- 
charides and subsequent coupling to the protein through 
a six-carbon “spacer” molecule, adipic acid. In adults, the 
immunogenicity of the first-generation meningococcal A 
and C conjugate vaccine appeared to be similar to that 
of a control unconjugated meningococcal polysaccharide 
vaccine.‘l A “second-generation” meningococcal C vac- 
cine was prepared using similar chemistry, except that 
very small oligomers (degree of polymerization [Dp] less 
than six monomers in length) were removed prior to 
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Figure 1. Strategy of conjugation of meningococcal oligosaccha- 
rides to CRM,9,, a cross-reactive, nontoxic, mutant diphtheria toxoid, 
used in the first-generation Chiron meningococcal A and C conjugate 
vaccine. The method is based on selective end-reducing group acti- 
vation of oligosaccharides and subsequent coupling to the protein via 
a six-carbon “spacer” molecule, adipic acid. ADOSu refers to the N- 
hydroxysuccinimide ester derivative of the adipic acid modified oligosac- 
charide. (Modified after Costantino P, et aLzO) 
conjugation. ‘* In phase I and II clinical trials in humans, 
both vaccines have been shown to be safe in infants, tod- 
dlers, and adults.20-26 Expanded clinical trials with the 
second-generation meningococcal C conjugate vaccine 
are currently in progress. 
Immunogenicity 
Toddlers 
In a study of American toddlers, 18 to 23 months of age, 
conducted at the University of California, Los Angeles 
(UCLA), two doses of the Chiron meningococcal A and 
C conjugate vaccine given 2 months apart elicited 50- to 
over lOO-fold higher bactericidal antibody responses to 
both group A and group C strains, compared to those 
observed in control toddlers vaccinated with two doses 
of licensed unconjugated meningococcal polysaccharide 
vaccine (Figure 2).24 Interestingly, the relative differences 
in immunogenicity between the conjugate and unconju- 
gated vaccines in this study were less striking when the 
antibody responses of the toddlers were measured by an 
enzyme-linked immunosorbent assay (ELISA), performed 
using a consensus protocol developed at the Centers For 
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Figure 2. Serum bactericidal antibody responses of American tod- 
dlers vaccinated with a meningococcal A and C oligosaccharide-CRM 
conjugate vaccine. Toddlers were given two doses of either Chiron 
meningococcal A and C oligosaccharide-CRM,,, conjugate vaccine, or 
meningococcal polysaccharide vaccine (Menomune, Connaught Lab- 
oratories, Inc., Swiftwater, PA). The injections were separated by 2 
months. Complement-mediated bactericidal activity was measured in 
serum obtained immediately before dose one (pre-) and 1 month after 
dose two (post-2). (Adapted from Lieberman JM, et aLz4) 
Disease Control (i.e., relative differences in antibody 
responses of twofold, instead of 50- to over loo-fold, as 
determined by the bactericidal assay). These results sug- 
gest that the anticapsular antibody elicited by this con- 
jugated meningococcal oligosaccharide vaccine is 
qualitatively different from that elicited by unconjugated 
meningococcal polysaccharide vaccine and, on a yg/mL 
basis, the conjugate-induced antibodies have a higher 
specific functional activity. Further, the ELISA is insensi- 
tive to these qualitative antibody differences, which may 
be important in protection against developing meningo- 
coccal disease. 
A second-generation Chiron meningococcal C poly- 
saccharide-protein conjugate vaccine, in which small sac- 
charide oligomers were removed prior to conjugation, 
was recently evaluated in toddlers 12 to 23 months of age 
in a multicenter Canadian study.22 This vaccine also 
elicited much higher serum bactericidal antibody 
responses after one or two injections than those observed 
in sera of control toddlers vaccinated with unconjugated 
polysaccharide vaccine. 
Infants 
The safety and immunogenicity of Chiron meningococ- 
cal conjugate vaccines also have been investigated in 
infants less than 6 months of age. The first study was 
performed with the first-generation combined A and C 
conjugate vaccine in Gambian infants immunized at 2, 
3, and 4 months of age, or 2 and 6 months, or 6 months 
of age.23 The anticapsular antibody responses of the 
infants to the A component of the conjugate vaccine 
were of similar magnitude to those of a control group 
receiving an unconjugated meningococcal A and C poly- 
saccharide vaccine. In contrast, the conjugate vaccine 
elicited two- to fourfold higher anticapsular antibody 
responses to meningococcal C polysaccharide than those 
observed in infants given the unconjugated polysaccha- 
ride vaccine. However, the elevated anti-C antibody con- 
centrations in the conjugate group began to decline 
within 3 months after vaccination. 
In the Gambian study, only ELISA antibody responses 
were reported. Based on the experience in the UCLA 
toddler study described above,24 the ELISA results may 
have underestimated the relative effectiveness of the con- 
jugate vaccine as compared to unconjugated polysac- 
charide, had the responses been assessed by serum 
bactericidal antibody. In a study in the United Kingdom, 
58 infants were vaccinated with the combined Chiron 
meningococcal A and C conjugate vaccine at 2, 3, and 4 
months of age.26 To date, bactericidal antibody responses 
to the group A vaccine have not been evaluated. How- 
ever, the infants showed excellent anti-meningococcal C 
bactericidal responses (geometric mean bactericidal titer 
[GMT] of < 1:4 prior to vaccination increasing to > 1:3082 
after three injections). However, by 14 months of age 
the GMT had declined to 1:lO. 
There are two other reports of the use of meningo- 
coccal C conjugate vaccines in infants. In one study, the 
second-generation Chiron meningococcal C polysaccha- 
ride-protein conjugate vaccine was given to infants in 
the United Kingdom at 2, 3, and 4 months of age.25 Pre- 
liminary results were limited to assays of sera obtained 
prior to vaccination and 1 month after the third injec- 
tion. The infants showed 25-fold increases in anticapsu- 
lar antibody concentrations, as measured by ELISA, and 
>50-fold increases in bactericidal titers. In the other study, 
a meningococcal serogroup C oligosaccharide-CRM,,, 
conjugate vaccine was prepared by Lederle Praxis Bio- 
logics (Rochester, NY) and administered to American 
infants at 2, 4, and 6 months of age.19 This conjugate vac- 
cine appeared to be well tolerated and elicited signifi- 
cant increases in serum anticapsular antibody 
concentration after two or three injections, as assessed 
by ELISA. 
INDUCTION OF IMMUNOLOGIC MEMORY 
In the studies of infants in Gambia or the United King- 
dom given the Chiron first-generation combined 
meningococcal A and C vaccine, serum antibody con- 
centrations began to decline rapidly after conjugate vac- 
cination.23 An important question, therefore, is whether 
or not the conjugate vaccination induced memory B cells 
that might allow the infants to respond rapidly with an 
increase in serum anticapsular antibody concentration 
upon encountering group A or C meningococci. To 
examine this question, participants in the Gambian study 
were re-vaccinated at 18 to 24 months of age with an 
unconjugated meningococcal polysaccharide vaccine.27 
Prior to the booster injection, the serum antibody 
concentrations to the A or C polysaccharides in the 
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Figure 3. Effect of conjugate vaccine priming on serum meningo- 
coccal C bactericidal antibody responses to unconjugated meningo- 
coccal polysaccharide vaccine. Toddlers in Gambia were boosted with 
a dose of unconjugated meningococcal polysaccharide vaccine (Men- 
povax A plus C, Biocine S.p.A., Siena, Italy) at a mean age of 19.7 
months. The subjects had been previously vaccinated either at 3 and 
6 months of age with unconjugated meningococcal polysaccharide, or 
at 2 and 6 months of age with Chiron meningococcal A and C oligosac- 
charide-CRM conjugate vaccine.*3 A group of control unprimed tod- 
dlers from the same study area were vaccinated with unconjugated 
polysaccharide vaccine for the first time. Data shown are bactericidal 
titers measured in sera obtained IO to 14 days after the polysaccha- 
ride booster vaccination. (Adapted from Leach A, et al.*? 
groups previously given the conjugate vaccine were not 
significantly different from those of toddlers of similar 
age who had not been previously vaccinated. However, 
as shown in Figure 3, the toddlers who had been primed 
with meningococcal conjugate vaccine at 2 and 6 months 
of age, and boosted with unconjugated meningococcal A 
and C polysaccharide vaccine, developed much higher 
anti-meningococcal C bactericidal titers after the booster 
vaccination than did Gambian toddlers of similar age 
immunized with unconjugated meningococcal polysac- 
charide vaccine for the first time. In contrast, the Gam- 
bian toddlers who had been primed with unconjugated 
meningococcal polysaccharide vaccine at 3 and 5 months 
of age showed significantly lower anti-C bactericidal 
responses to the polysaccharide booster injection than 
the control toddlers vaccinated for the first time (see Fig- 
ure 3). This result confirms previous data suggesting that 
immunization at an early age with unconjugated meningo- 
coccal group C polysaccharide vaccine induces immuno- 
logic tolerance and impairs the ability to respond to a 
subsequent immunization with unconjugated meningo- 
coccal polysaccharide vaccines. The clinical importance 
of this finding is unknown. However, immunologic tol- 
erance to meningococcal C polysaccharide could enhance 
susceptibility to developing invasive meningococcal dis- 
ease by impairing the ability of the child to develop a 
protective serum anticapsular antibody response upon 
encountering the organism. 
Although the Gambian toddlers who had been given 
conjugate vaccine as infants were primed for memory 
antibody responses to meningococcal C polysaccharide, 
Figure 4. Effect of conjugate vaccine priming on serum meningo- 
coccal A bactericidal antibody responses to unconjugated meningo- 
coccal polysaccharide vaccine. Methods as described in Figure 3. 
similar priming was not observed to the group A poly- 
saccharide: that is, the magnitude of the anti-A antibody 
response to the booster injection of unconjugated poly- 
saccharide vaccine was not significantly higher in the 
conjugate-primed group than in Gambian toddlers vac- 
cinated with unconjugated meningococcal polysaccha- 
ride for the first time (Figure 4). Further, in contrast to 
meningococcal C polysaccharide, evidence of immuno- 
logic tolerance to meningococcal A polysaccharide was 
not observed in the toddlers previously given the uncon- 
jugated polysaccharide vaccine at 3 and 5 months of age 
(see Figure 4). Indeed, the toddlers vaccinated with 
unconjugated polysaccharide vaccine as infants appeared 
to have shown secondary antibody responses to the 
serogroup A polysaccharide booster. These data confirm 
the results of many previous studies indicating that group 
A and group C meningococcal unconjugated polysac- 
charide vaccines have very different immunologic prop- 
erties*: specifically, meningococcal A polysaccharide 
vaccines are both immunogenic and protective in early 
infancy,3 and may even prime for secondary antibody 
responses to a subsequent injection.5 Meningococcal C 
polysaccharide vaccine shows none of these properties. 
The immunologic basis for these differences remains 
unknown. 
Recently, toddlers who participated in the UCLA study 
of the Chiron first-generation meningococcal A and C con- 
jugate vaccine were also given a booster injection of 
unconjugated meningococcal polysaccharide vaccine 
approximately 1 year later. 28 The group that had been 
primed with the conjugate vaccine showed evidence of 
induction of memory B cells to both the serogroup A and 
C polysaccharides, as evidenced by high serum bacteri- 
cidal booster antibody responses. These results are in con- 
trast to those of the Gambian infants given this conjugate 
vaccine in whom evidence of induction of memory B cells 
was limited to the serogroup C polysaccharide, and not 
the serogroup A polysaccharide (see above).27 Further 
studies of immunologic priming induced by meningo- 
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coccal A conjugate vaccines at different ages and in dif- 
ferent populations are needed to clarify this discrepancy 
MENINGOCOCCAL B POLYSACCHARIDE-PROTEIN 
CONJUGATE VACCINES 
Investigational polysaccharide-protein conjugate vaccines 
also have been prepared for prevention of disease caused 
by serogroup B organisms. 18,29-31 In general, these conju- 
gates are much less immunogenic than those prepared 
with serogroup A or C polysaccharides. However, one 
promising immunogenic meningococcal B vaccine can- 
didate is a conjugate in which the polysaccharide com- 
ponent has been modified by substitution of N-propionyl 
(NPr) groups for iV-acetyl (NAc) groups (NPr-meningo- 
coccal B polysaccharide).30 This vaccine is reported to 
elicit IgG bactericidal antibody responses in mice, rabbits, 
and subhuman primates. However, it will be a difficult 
task to prove that such vaccines are safe in humans, 
because, in mice, data suggest that NPr-meningococcal B 
polysaccharide-protein conjugate vaccines induce anti- 
NPr-meningococcal B polysaccharide antibodies that 
cross-react with native NAc-meningococcal B polysac- 
charide and also appear to have autoantibody activity.3z 
Whether or not the use of alternative substitutions on 
the polysaccharide, such as N-butanoyl,33 or the admin- 
istration of the NPr-meningococcal B polysaccharide con- 
jugate vaccine with new adjuvants3* will truly permit an 
antibody response in humans that is functional, entirely 
pathogen-specific, and not cross-reactive with host anti- 
gens, remains to be ascertained. 
CONCLUSIONS AND THE FUTURE 
Meningococcal A and C conjugate vaccines hold enor- 
mous promise for providing solid long-term protection to 
infant age groups that are currently poorly protected by 
licensed unconjugated meningococcal polysaccharide 
vaccines. Further, third-generation conjugate vaccines are 
under development in which the acquisition of immu- 
nity is accelerated and immunogenicity is enhanced by 
administration of the conjugate vaccine with novel adju- 
vants.35 The use of adjuvants suitable for humans holds 
promise for decreasing the number of doses of conju- 
gate vaccine required for induction of immunity in 
infants. This approach also may be useful for enhancing 
or maintaining immunogenicity of future multicompo- 
nent conjugate vaccines. For prevention of group B 
meningococcal disease, adjuvanted polysaccharide-pro- 
tein conjugate vaccines also may prove to be immuno- 
genic and protective, and help avoid some of the safety 
issues of inducing anticapsular autoantibody. However, 
for prevention of meningococcal B disease, alternative 
approaches may be needed to avoid completely the safety 
concerns of inducing anticapsular antibodies with auto- 
antibody reactivity. 
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